Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins

Cytokine

Volumn 58, Issue 1, 2012, Pages 118-128

  Yano, Junko ^a   Noverr, Mairi C ^a   Fidel Jr , Paul L ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida albicans; Epithelial cells; Inflammation; S100 alarmins; Vaginitis

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CHEMOTACTIC FACTOR; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PROTEIN ANTIBODY; PROTEIN S 100; S100 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ASYMPTOMATIC INFECTION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOKINE RESPONSE; DENDRITIC CELL; ENTERITIS; EPITHELIUM CELL; FUNGUS IMMUNITY; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION SENSITIVITY; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STREPTOCOCCUS PNEUMONIA; TH1 CELL; TH17 CELL; TH2 CELL; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINA MUCOSA; VAGINAL EPITHELIUM CELL;

ADAPTIVE IMMUNITY; ANIMALS; CALGRANULIN A; CALGRANULIN B; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; CYTOKINES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNITY, INNATE; MICE; MUCOUS MEMBRANE; NEUTROPHILS; VAGINA;

ANIMALIA; CANDIDA; CANDIDA ALBICANS;

EID: 84857452982     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.021     Document Type: Review

References (130)

1. Sobel J.D., Faro S., Force R., Foxman B., Ledger W.J., Nyirjesy P.R., et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998, 178:203-211.
2. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14:S148-S153.
3. Fidel P.L. Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 2002, 40:359-375.
4. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 1999, 2:363-367.
5. Romani L., Mencacci A., Tonnetti L., Spaccapelo R., Cenci E., Puccetti P., et al. IL-12 is both required and prognostic in vivo for T-helper type 1 differentiation in murine candidiasis. J immunol 1994, 152:5167-5175.
6. Mathur S., Virella G., Koistinen J., Horger E.O., Mahvi T.A., Fudenberg H.H. Humoral immunity in vaginal candidiasis. Infect Immun 1977, 15:287-294.
7. Kirkpatrick C.H., Rich R.R., Bennett J.E. Chronic mucocutaneous candidiasis: Model building in cellular immunity. Ann Intern Med 1971, 74:955-978.
8. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
9. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009, 206:299-311.
10. Eyerich K., Foerster S., Rombold S., Seidl H.P., Behrendt H., Hofmann H., et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 2008, 128:2640-2645.
11. Huang W., Na L., Fidel P.L., Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004, 190:624-631.
12. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2680-2682.
13. Ferwerda B., Ferwerda G., Plantinga T.S., Willment J.A., van Spriel A.B., Venselaar H., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361:1798-1801.
14. Lev-Sagie A., Nyirjesy P., Tarangelo N., Bongiovanni A.M., Bayer C., Giraldo Linhares.I.M., et al. Hyaluronan in vaginal secretions: association with recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2009, 201:206. e1-206.e5.
15. Klein R.S., Harris C.A., Small C.B., Moll B., Lesser M., Friedland G.H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984, 311:354-357.
16. Clift R.A. Candidiasis in the transplant patient. Amer J Med 1984, 77(Suppl. 4D):34-38.
17. Samaranayake L.P. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992, 73:171-180.
18. Romani L., Puccetti P., Bistoni F. Biological role of Th cell subsets in candidiasis. Th1 and Th2 cells in health and disease 1996, 114-137. Karger, Farmington, CT. S. Romagnani (Ed.).
19. Mathews H.L., Witek-Janusek L. Host defense against oral, esophageal, and gastrointestinal candidiasis. Candida and Candidiasis 2002, 179-192. ASM Press, Washington, DC. R.A. Carderone (Ed.).
20. Sohnle P.G., Bhatti M., Wagner D.K. Immunology of cutaneous candidiasis. Candida and Candidiasis 2002, 211-221. ASM Press, Washington, DC. R. Calderone (Ed.).
21. Fidel P.L., Sobel J.D. The role of cell-mediated immunity in candidiasis. Trends Micro 1994, 2:202-206.
22. Fong I.W., McCleary P., Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol 1992, 166:887-890.
23. Hobbs J.R., Briden D., Davidson F., Kahan M., Oates J.K. Immunological aspects of candidal vaginitis. Proc R Soc Med 1977, 70:11-14.
24. Mendling W., Koldovsky U. Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses. Infect Dis Obstet Gynecol 1996, 4:225-231.
25. Cu-Uvin S., Hogan J.W., Warren D., Klein R.S., Peipert J., Schuman P., et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-serpositive and high-risk HIV-seronegative women. Clin Infect Dis 1999, 29:1145-1150.
26. White M.H. Is vulvovaginal candidiasis an AIDS-related illness. Clin Infect Dis 1996, 22(Suppl. 2):S124-S127.
27. Leigh J.E., Barousse M., Swoboda R.K., Myers T., Hager S., Wolf N.A., et al. Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiaisis. J Infect Dis 2001, 183:277-285.
28. Fidel P.L., Luo W., Steele C., Chabain J., Baker M., Wormley F.L. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999, 67:3135-3140.
29. Taylor B.N., Saavedra M., Fidel P.L. Local Th1/Th2 cytokine production during experimental vaginal candidiasis. Med Mycol 2000, 38:419-431.
30. Saavedra M., Taylor B., Lukacs N.W., Fidel P.L. Local production of chemokines during experimental vaginal candidiasis. Infect Immun 1999, 67:5820-5829.
31. Fidel P.L., Wolf N.A., KuKuruga M.A. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 1996, 64:3793-3799.
32. Nandi D., Allison J.P. Phenotypic analysis and gamma/delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol 1991, 147:1773-1778.
33. + ab T cells of the murine female genital tract: a phenotypically distinct T cell lineage that rapidly proliferates in response to systemic T cell activation stimuli. Int immunol 1995, 7:1763-1769.
34. Barousse M., Van Der Pol B.J., Fortenberry D., Orr D., Fidel P.L. Vaginal yeast colonization, prevalence of vaginitis, and associated local immunity in adolescents. Sex Trans Infect 2004, 80:48-53.
35. Fidel P.L., Barousse M., Espinosa T., Chesson R.R., Dunlap K. Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle. Med Mycol 2003, 41:97-109.
36. Santoni G., Boccanera M., Adriani D., Lucciarini R., Amantini C., Morrone S., et al. Immune cell-mediated protection against vaginal candidiasis: Evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect Immun 2002, 70:4791-4797.
37. De Bernardis F., Santoni G., Boccanera M., Spreghini E., Adriani D., Morelli L., et al. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 2000, 68:3297-3304.
38. Schaller M., Korting H.C., Borelli C., Hamm G., Hube B. Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun 2005, 73:2758-2765.
39. Wormley F.L., Steele C., Wozniak K., Fujihashi K., McGhee J.R., Fidel P.L. Resistance of TCR d-chain knock-out mice to experimental Candida vaginitis. Infect Immun 2001, 69:7162-7164.
40. Wormley F.L., Chaiban J., Fidel P.L. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect Immun 2001, 69:5072-5079.
41. LeBlanc D.M., Barousse M.M., Fidel P.L. A role for dendritic cells in immunoregulation during experimental vaginal candidiasis. Infect Immun 2006, 74:3213-3221.
42. Babula O., Lazdane G., Kroica J., Linhares I.M., Ledger W.J., Witkin S.S. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005, 40:1258-1262.
43. Chen S., Li S., Wu Y., Liu Z., Li J. Local expression of vaginal Th1 and Th2 cytokines in murine vaginal candidiasis under different immunity conditions. J Huazhong Univ Sci Technolog Med Sci 2008, 28:476-479.
44. De Bernardis F., Santoni G., Boccanera M., Lucciarini R., Arancia S., Sandini S., et al. Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes. FEMS Yeast Res 2010, 10:432-440.
45. De Bernardis F., Boccanera M., Adriani D., Spreghini E., Santoni G., Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997, 65:3399-3405.
46. Han Y., Morrison R.P., Cutler J.E. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998, 66:5771-5776.
47. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995, 63:4211-4218.
48. Rigg D., Miller M.M., Metzger W.J. Recurrent allergic vulvovaginitis: Treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990, 162:332-336.
49. Witkin S.S. Immunologic factors influencing susceptibility to recurrent candidal vaginitis. Clin Obstet Gynecol 1991, 34:662-668.
50. Witkin S.S., Kalo-Klein A., Galland L., Teich M., Ledger W.J. Effect of Candida albicans plus histamine on prostaglandin E2 production by peripheral blood mononuclear cells from healthy women and women with recurrent candidal vaginitis. J Infect Dis 1991, 164:396-399.
51. Fan S.R., Liao Q.P., Liu X.P., Liu Z.H., Zhang D. Vaginal allergic response in women with vulvovaginal candidiasis. Int J Gynaecol Obstet 2008, 101:27-30.
52. Fidel P.L., Ginsburg K.A., Cutright J.L., Wolf N.A., Leaman D., Dunlap Sobel.J.D. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: Evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997, 176:728-739.
53. Conti H.R., Baker O., Freeman A.F., Jang W.S., Holland S.M., Li R.A., et al. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol 2011, 4:448-455.
54. Kolls JK, McCray Jr PB, Chan YR. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 8 A.D.; 8: 829-35.
55. Urban C.F., Ermert D.S.M., Abu-Abed U., Goosman C., Nacken W., Brinkmann V., et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009, 5:e1000639.
56. Feinen B., Jerse A.E., Gaffen S.L., Russel M.W. Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol 2010, 3:312-321.
57. Scurlock A.M., Frazer L.C., Andrews C.W., O'Connell C.M., Foote I.P., Bailey S.L., et al. Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection. Infect Immun 2011, 79:1349-1362.
58. Pietrella D., Rachini A., Pines M., Pandey N., Mosci P., Bistoni F., et al. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS ONE 2011, 6:e22770.
59. Black C.A., Eyers F.M., Russell A., Dunkley M.L., Clancy R.L., Beagley K.W. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 1998, 66:1273-1275.
60. Parr M.B., Parr E.L. Langerhans cells and T lymphocyte subsets in the murine vagina and cervix. Biol Reprod 1991, 44:491-498.
61. Steele C., Ozenci H., Luo W., Scott M., Fidel P.L. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 1999, 37:251-260.
62. Steele C., Ratterree M., Fidel P.L. Differential susceptibility to experimental vaginal candidiasis in macaques. J Infect Dis 1999, 180:802-810.
63. Barousse M.M., Steele C., Dunlap K., Espinosa T., Boikov D., Sobel J.D., et al. Growth Inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 2001, 184:1489-1493.
64. Steele C., Leigh J.E., Swoboda R.K., Fidel P.L. Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 2000, 182:1479-1485.
65. Yano J., Lilly E., Steele C., Fortenberry D., Fidel P.L. Oral and vaginal epithelial cell anti-Candida activity is acid-labile and does not require live epithelial cells. Oral Microbiol Immunol 2005, 20:199-205.
66. Lilly E.A., Yano J., Fidel P.L. Annexin-A1 identified as the oral epithelial cell anti-Candida effector moiety. Mol Oral Microbiol 2010, 25:293-304.
67. Barousse M.M., Espinosa T., Dunlap K., Fidel P.L. Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. Infect Immun 2005, 73:7765-7767.
68. Vylkova S., Nayyar N., Li W., Edgerton M. Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption. Antimicrob Agents Chemother 2007, 51:154-161.
69. Peters B.M., Zhu J., Fidel P.L., Scheper M.A., Hackett W., El Shaye S., et al. Protection of the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection. FEMS Yeast Res 2010, 10:597-604.
70. Fidel P.L., Barousse M., Espinosa T., Ficarra M., Sturtevant J., Martin D.H., et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004, 72:2939-2946.
71. Yano J., Lilly E., Barousse M., Fidel P.L. Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect Immun 2010, 78:5126-5137.
72. Fidel P.L. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 2007, 57:2-12.
73. Black C.A., Eyers F.M., Dunkley M.L., Clancy R.L., Beagley K.W. Major histocompatibility haplotype does not impact the course of experimentally induced murine vaginal candidiasis. Lab Anim Sci 1999, 49:668-672.
74. Clemons K.V., Spearow J.L., Parmar R., Espiritu M., Stevens D.A. Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun 2004, 72:4878-4880.
75. Calderon L., William R., Martinez M., Clemons K.V., Stevens D.A. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003, 41:143-147.
76. Fidel P.L., Cutright J.L., Steele C. Effects of Reproductive hormones on experimental vaginal candidiasis. Infect Immun 2000, 68:651-657.
77. Fidel P.L., Sobel J.D. Murine models of Candida vaginal infections. Experimental models in antimicrobial chemotherapy 1999, 741-748. Academic Press Ltd., London, UK. O. Zak, M. Sande (Eds.).
78. Fidel P.L., Cutright J.L., Tait L., Sobel J.D. A murine model of Candida glabrata vaginitis. J Infect Dis 1996, 173:425-431.
79. Sohnle P.G., Hahn B.L., Santhanagopalan V. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996, 174:1369-1372.
80. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995, 37:417-429.
81. Ehrchen J.M., Sunderkötter C., Foell D., Vogl T., Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009, 86:557-566.
82. Foell D., Wittkowski H., Ren Z., Turton J., Pang G., Daebritz J., et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008, 216:183-192.
83. Gebhardt C., Németh J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631.
84. Kumar R.K., Yang Z., Bilson S., Thliveris S., Cooke B.E., Geczy C.L. Dimeric S100A8 in human neutrophils is diminished after phagocytosis. J Leukoc Biol 2001, 70:59-64.
85. Ross K.F., Herzberg M.C. Calprotectin expression by gingival epithelial cells. Infect Immun 2001, 69:3248-3254.
86. Ryckman C., Vandal K., Rouleau P., Talbot M., Tessier P.A. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003, 170:3233-3242.
87. Sims G.P., Rowe D.C., Rietdijik S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388.
88. Hashemi F.B., Mollenhauer J., Madsen L.D., Sha B.E., Nacken W., Moyer M.B., et al. Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS 2001, 15:441-449.
89. Abtin A., Eckhart L., Gläser R., Gmeiner R., Mildner M., Tschachler E. The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. J Invest Dermatol 2010, 130:2423-2430.
90. Gebhardt C., Breitenbach U., Tuckermann J.P., Dittrich B.T., Richter K.H., Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 2002, 21:4266-4276.
91. Hummerich L., Muller R., Hess J., Kokocinski F., Hahn M., Furstenberger G., et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 2006, 25:111-121.
92. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
93. Cheng P., Crozo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.
94. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., et al. MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049.
95. Brandtzaeg P., Gabrielsen T.O., Dale I., Muller F., Steinbakk M., Fagerhol M.K. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Bio 1995, 371:201-206.
96. Sohnle P.G., Hunter M.J., Hahn B., Chazin W.J. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 2000, 182:1272-1275.
97. Chen Y.S., Yan W., Geczy C.L., Brown M.A., Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R39.
98. Hammer H.B., Odegard S., Fagerhol M.K., Landewé R., van der Heijde D., Uhlig T., et al. Calprotectin (a major leukocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1093-1097.
99. Youssef P., Roth J., Frosch M., Costello P., Fitzgerald O., Sorg C., et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999, 26:2523-2528.
100. van Lent P.L., Grevers L., Blom A.B., Sloetjes A., Mort J.S., Vogl T., et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008, 67:1750-1758.
101. Rugtveit J., Nilsen E.M., Bakka A., Carlsen H., Brandtzaeg P., Scott H. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenter 1997, 112:1493-1505.
102. Sarsfield P., Jones D.B., Wright D.H. Accessory cells in physiological lymphoid tissue from the intestine: an immunohistochemical study. Histopathology 1996, 28:213-219.
103. Waraich T., Sarsfield P., Wright D.H. The accessory cell populations in ulcerative colitis: a comparison between the colon and appendix in colitis and acute appendicitis. Hum Pathol 1997, 28:297-303.
104. Roth J., Vogl T., Sorg C., Sunderkötter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. TRENDS Immunol 2003, 24:155-158.
105. Leach S.T., Yang Z., Messina I., Sorg C., Geczy C.L., Cunningham A.M., et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007, 42:1321-1331.
106. Fagerberg U.L., Lööf L., Lindholm J., Hansson L.O., Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 45:414-420.
107. Qin F., Song Y., Li Z., Zhao Y., Zhang Y., Geng L. S100A8/A9 induces apoptosis and inhibits metastasis of CasKi human cervical cancer cells. Pathol Oncol Res 2010, 16:353-360.
108. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006, 8:1369-1375.
109. Kunimi K., Maegawa M., Kamada M., Yamamoto S., Yasui T., Matsuzaki T., et al. Myeloid-related protein-8/14 is associated with proinflammatory cytokines in cervical mucus. J Reprod Immunol 2006, 71:3-11.
110. Payen D., Lukaszewicz A.C., Belikova I., Faivre V., Gelin C., Russwurm S., et al. Gene profiling in human blood leukocytes during recovery from septic shock. Intensive Care Med 2008, 34:1371-1376.
111. Raquil M.A., Anceriz N., Rouleau P., Tessier P.A. Blockage of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia. J Immunol 2008, 180:3366-3374.
112. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived supressor cells. J Immunol 2008, 181:4666-4675.
113. Frosch M., Ahlmann M., Vogl T., Wittkowski H., Wulffraat N., Foell Roth.J. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:883-891.
114. De Bernardis F., Lucciarini R., Boccanera M., Amantini C., Arancia S., Morrone S., et al. Phenotypic and functional characterization of vaginal cells in a rat model of Candida albicans vaginitis. Infect Immun 2006, 74:4282-4294.
115. Weissenbacher T.M., Witkin S.S., Gingelmaier A., Scholz C., Friese K., Mylonas I. Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol 2009, 144:59-63.
116. Riau A.K., Wong T.T., Beuerman R.W., Tong L. Calcium-binding S100 protein expression in pterygium. Mol Vis 2009, 15:335-342.
117. Zhou L., Beuerman R.W., Ang L.P., Chan C.M., Li S.F., Chew F.T., et al. Elevation of human alpha-defensins and S100 calcium-binding proteins A8 and A9 in tear fluid of patients with pterygium. Invest Ophthalmol Vis Sci 2009, 50:2077-2086.
118. Németh J., Stein I., Haag D., Riehl A., Longerich T., Horwitz E., et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009, 50:1251-1262.
119. Ryckman C., Robichaud G.A., Roy J., Cantin R., Tremblay M.J., Tessier P.A. HIV-1 transcrition and virus production are both accentuated by the proinflammatory myeloid-related proteins in human CD4+ T lymphocytes. J Immunol 2002, 169:3307-3313.
120. Sunderkötter C.H., Tomimori-Yamashita J., Nix V., Maeda S.M., Sindrilaru A., Mariano M., et al. High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. Immunology 2004, 111:472-480.
121. Reyes L., Alvarez S., Allam A., Reinhard M., Brown M.B. Complicated urinary tract infection is associated with uroepithelial expression of proinflammatory protein S100A8. Infect Immun 2009, 77:4265-4274.
122. Benoit S., Toksoy A., Ahlmann M., Schmidt M., Sunderkötter C., Foell D., et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol 2006, 155:62-66.
123. Lorenz E., Muhlebach M.S., Tessier P.A., Alexis N.E., Duncan Hite R., Seeds M.C., et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008, 102:567-573.
124. McMorran B.J., Patat S.A., Carlin J.B., Grimwood K., Jones A., Armstrong D.S., et al. Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis. Clin Chem 2007, 53:1782-1791.
125. Sweet S.P., Denbury A.N., Challacombe S.J. Salivary calprotectin levels are raised in patients with oral candidiasis or Sjogrens syndrome but decreased by HIV infection. Oral Microbiol Immunol 2001, 16:119-123.
126. Lood C., Stenström M., Tydén H., Gullstrand B., Källberg E., Leanderson T., et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R60.
127. McCormick A., Rahimi F., Bobryshev Y.V., Gaus K., Zreigat H., Cai H., et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005, 280:41521-41529.
128. Croce K., Gao H., Wang Y., Mooroka T., Sakuma M., Shi C., et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009, 120:427-436.
129. Ryckman C., McColl S.R., Vandal K., de Médicis R., Lussier A., Poubelle P.E., et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003, 48:2310-2320.
130. Tong L., Zhou L., Beuerman R.W., Zhao S.Z., Li X.R. Association of tear proteins with Meibomian gland disease and dry eye symptoms. Br J Ophthalmol 2011, 95:848-852.